Loading...
Market
What will be the total revenue generated by KarXT in its first full year on the market in 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Financial reports from Bristol Myers Squibb
Story
KarXT by Bristol Myers Squibb: First Novel Schizophrenia Drug in 70 Years Shows 30% Symptom Improvement for 1 in 300 People
Oct 17, 2024, 12:00 PM
KarXT, a new oral medication developed by Bristol Myers Squibb (BMS), aims to be the first significant advancement in schizophrenia treatment in over 70 years. This twice-daily pill is designed to address the severe mental health condition that affects approximately 1 in 300 people globally. Early reports indicate that patients using KarXT are experiencing a 30% improvement in symptoms, while also avoiding the severe side effects commonly associated with older schizophrenia medications. The development of KarXT has been supported by research funded by the Wellcome Trust, highlighting the potential for pharmaceutical innovation to enhance treatment options for millions affected by this condition.
View original story
Similar markets
Less than $250 million • 25%
$250 million to $499 million • 25%
$500 million to $749 million • 25%
$750 million or more • 25%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative impact • 25%
< 50,000 • 25%
50,000 - 100,000 • 25%
100,000 - 200,000 • 25%
> 200,000 • 25%
Yes • 50%
No • 50%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%